Seroatlas · Human Serome Atlas

CELSR3

Cadherin EGF LAG seven-pass G-type receptor 3

Also known as: ADGRC3, CDHF11, CELR3_HUMAN, EGFL1, FMI1, HFMI1, MEGF2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NYQ7
Gene: CELSR3
Ensembl: ENSG00000008300
Chromosome: 3
Canonical length: 3312 aa
Protein class: G-protein coupled receptors, Plasma proteins, Predicted membrane proteins

OverviewNCBI Gene

This gene belongs to the flamingo subfamily, which is included in the cadherin superfamily. The flamingo cadherins consist of nonclassic-type cadherins that do not interact with catenins. They are plasma membrane proteins containing seven epidermal growth factor-like repeats, nine cadherin domains and two laminin A G-type repeats in their ectodomain. They also have seven transmembrane domains, a characteristic feature of their subfamily. The encoded protein may be involved in the regulation of contact-dependent neurite growth and may play a role in tumor formation. [provided by RefSeq, Jun 2013]

Canonical amino-acid sequenceUniProt

3312 residues, UniProt reviewed canonical sequence.

>Q9NYQ7|CELSR3
     1  MMARRPPWRG LGGRSTPILL LLLLSLFPLS QEELGGGGHQ GWDPGLAATT GPRAHIGGGA
    61  LALCPESSGV REDGGPGLGV REPIFVGLRG RRQSARNSRG PPEQPNEELG IEHGVQPLGS
   121  RERETGQGPG SVLYWRPEVS SCGRTGPLQR GSLSPGALSS GVPGSGNSSP LPSDFLIRHH
   181  GPKPVSSQRN AGTGSRKRVG TARCCGELWA TGSKGQGERA TTSGAERTAP RRNCLPGASG
   241  SGPELDSAPR TARTAPASGS APRESRTAPE PAPKRMRSRG LFRCRFLPQR PGPRPPGLPA
   301  RPEARKVTSA NRARFRRAAN RHPQFPQYNY QTLVPENEAA GTAVLRVVAQ DPDAGEAGRL
   361  VYSLAALMNS RSLELFSIDP QSGLIRTAAA LDRESMERHY LRVTAQDHGS PRLSATTMVA
   421  VTVADRNDHS PVFEQAQYRE TLRENVEEGY PILQLRATDG DAPPNANLRY RFVGPPAARA
   481  AAAAAFEIDP RSGLISTSGR VDREHMESYE LVVEASDQGQ EPGPRSATVR VHITVLDEND
   541  NAPQFSEKRY VAQVREDVRP HTVVLRVTAT DRDKDANGLV HYNIISGNSR GHFAIDSLTG
   601  EIQVVAPLDF EAEREYALRI RAQDAGRPPL SNNTGLASIQ VVDINDHIPI FVSTPFQVSV
   661  LENAPLGHSV IHIQAVDADH GENARLEYSL TGVAPDTPFV INSATGWVSV SGPLDRESVE
   721  HYFFGVEARD HGSPPLSASA SVTVTVLDVN DNRPEFTMKE YHLRLNEDAA VGTSVVSVTA
   781  VDRDANSAIS YQITGGNTRN RFAISTQGGV GLVTLALPLD YKQERYFKLV LTASDRALHD
   841  HCYVHINITD ANTHRPVFQS AHYSVSVNED RPMGSTIVVI SASDDDVGEN ARITYLLEDN
   901  LPQFRIDADS GAITLQAPLD YEDQVTYTLA ITARDNGIPQ KADTTYVEVM VNDVNDNAPQ
   961  FVASHYTGLV SEDAPPFTSV LQISATDRDA HANGRVQYTF QNGEDGDGDF TIEPTSGIVR
  1021  TVRRLDREAV SVYELTAYAV DRGVPPLRTP VSIQVMVQDV NDNAPVFPAE EFEVRVKENS
  1081  IVGSVVAQIT AVDPDEGPNA HIMYQIVEGN IPELFQMDIF SGELTALIDL DYEARQEYVI
  1141  VVQATSAPLV SRATVHVRLV DQNDNSPVLN NFQILFNNYV SNRSDTFPSG IIGRIPAYDP
  1201  DVSDHLFYSF ERGNELQLLV VNQTSGELRL SRKLDNNRPL VASMLVTVTD GLHSVTAQCV
  1261  LRVVIITEEL LANSLTVRLE NMWQERFLSP LLGRFLEGVA AVLATPAEDV FIFNIQNDTD
  1321  VGGTVLNVSF SALAPRGAGA GAAGPWFSSE ELQEQLYVRR AALAARSLLD VLPFDDNVCL
  1381  REPCENYMKC VSVLRFDSSA PFLASASTLF RPIQPIAGLR CRCPPGFTGD FCETELDLCY
  1441  SNPCRNGGAC ARREGGYTCV CRPRFTGEDC ELDTEAGRCV PGVCRNGGTC TDAPNGGFRC
  1501  QCPAGGAFEG PRCEVAARSF PPSSFVMFRG LRQRFHLTLS LSFATVQQSG LLFYNGRLNE
  1561  KHDFLALELV AGQVRLTYST GESNTVVSPT VPGGLSDGQW HTVHLRYYNK PRTDALGGAQ
  1621  GPSKDKVAVL SVDDCDVAVA LQFGAEIGNY SCAAAGVQTS SKKSLDLTGP LLLGGVPNLP
  1681  ENFPVSHKDF IGCMRDLHID GRRVDMAAFV ANNGTMAGCQ AKLHFCDSGP CKNSGFCSER
  1741  WGSFSCDCPV GFGGKDCQLT MAHPHHFRGN GTLSWNFGSD MAVSVPWYLG LAFRTRATQG
  1801  VLMQVQAGPH STLLCQLDRG LLSVTVTRGS GRASHLLLDQ VTVSDGRWHD LRLELQEEPG
  1861  GRRGHHVLMV SLDFSLFQDT MAVGSELQGL KVKQLHVGGL PPGSAEEAPQ GLVGCIQGVW
  1921  LGSTPSGSPA LLPPSHRVNA EPGCVVTNAC ASGPCPPHAD CRDLWQTFSC TCQPGYYGPG
  1981  CVDACLLNPC QNQGSCRHLP GAPHGYTCDC VGGYFGHHCE HRMDQQCPRG WWGSPTCGPC
  2041  NCDVHKGFDP NCNKTNGQCH CKEFHYRPRG SDSCLPCDCY PVGSTSRSCA PHSGQCPCRP
  2101  GALGRQCNSC DSPFAEVTAS GCRVLYDACP KSLRSGVWWP QTKFGVLATV PCPRGALGAA
  2161  VRLCDEAQGW LEPDLFNCTS PAFRELSLLL DGLELNKTAL DTMEAKKLAQ RLREVTGHTD
  2221  HYFSQDVRVT ARLLAHLLAF ESHQQGFGLT ATQDAHFNEN LLWAGSALLA PETGDLWAAL
  2281  GQRAPGGSPG SAGLVRHLEE YAATLARNME LTYLNPMGLV TPNIMLSIDR MEHPSSPRGA
  2341  RRYPRYHSNL FRGQDAWDPH THVLLPSQSP RPSPSEVLPT SSSIENSTTS SVVPPPAPPE
  2401  PEPGISIIIL LVYRTLGGLL PAQFQAERRG ARLPQNPVMN SPVVSVAVFH GRNFLRGILE
  2461  SPISLEFRLL QTANRSKAIC VQWDPPGLAE QHGVWTARDC ELVHRNGSHA RCRCSRTGTF
  2521  GVLMDASPRE RLEGDLELLA VFTHVVVAVS VAALVLTAAI LLSLRSLKSN VRGIHANVAA
  2581  ALGVAELLFL LGIHRTHNQL VCTAVAILLH YFFLSTFAWL FVQGLHLYRM QVEPRNVDRG
  2641  AMRFYHALGW GVPAVLLGLA VGLDPEGYGN PDFCWISVHE PLIWSFAGPV VLVIVMNGTM
  2701  FLLAARTSCS TGQREAKKTS ALTLRSSFLL LLLVSASWLF GLLAVNHSIL AFHYLHAGLC
  2761  GLQGLAVLLL FCVLNADARA AWMPACLGRK AAPEEARPAP GLGPGAYNNT ALFEESGLIR
  2821  ITLGASTVSS VSSARSGRTQ DQDSQRGRSY LRDNVLVRHG SAADHTDHSL QAHAGPTDLD
  2881  VAMFHRDAGA DSDSDSDLSL EEERSLSIPS SESEDNGRTR GRFQRPLCRA AQSERLLTHP
  2941  KDVDGNDLLS YWPALGECEA APCALQTWGS ERRLGLDTSK DAANNNQPDP ALTSGDETSL
  3001  GRAQRQRKGI LKNRLQYPLV PQTRGAPELS WCRAATLGHR AVPAASYGRI YAGGGTGSLS
  3061  QPASRYSSRE QLDLLLRRQL SRERLEEAPA PVLRPLSRPG SQECMDAAPG RLEPKDRGST
  3121  LPRRQPPRDY PGAMAGRFGS RDALDLGAPR EWLSTLPPPR RTRDLDPQPP PLPLSPQRQL
  3181  SRDPLLPSRP LDSLSRSSNS REQLDQVPSR HPSREALGPL PQLLRAREDS VSGPSHGPST
  3241  EQLDILSSIL ASFNSSALSS VQSSSTPLGP HTTATPSATA SVLGPSTPRS ATSHSISELS
  3301  PDSEVPRSEG HS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CELSR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0
Highest tissue expression: 15 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 15 nTPM
pituitary gland: 6.8 nTPM
cerebral cortex: 3.9 nTPM
retina: 3.6 nTPM
hypothalamus: 2.3 nTPM
basal ganglia: 2.1 nTPM

Single-cell type

retinal horizontal cells: 18 nCPM
cone photoreceptor cells: 15 nCPM
gonadotrophs: 15 nCPM
somatotrophs: 14 nCPM
lactotrophs: 13 nCPM
brain inhibitory neurons: 13 nCPM

Immune cell

naive CD8 T-cell: 0.2 nTPM
gdT-cell: 0.1 nTPM
T-reg: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

cerebellum: 35 nTPM
cerebral cortex: 31 nTPM
basal ganglia: 25 nTPM
hippocampal formation: 23 nTPM
white matter: 21 nTPM
hypothalamus: 21 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CELSR3.

Disease | GeneticClinVar

13 pathogenic / likely-pathogenic of 528 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

See cases
Congenital anomalies of kidney and urinary tract 1

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.25
gnomAD pLI: 1
gnomAD missense Z: 4.08
DepMap mean gene effect: -0.14
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CELSR3 as an antibody target. Whether an autoantibody or antibody against CELSR3 could matter depends on whether native CELSR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CELSR3 is annotated at the cell surface, where native CELSR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CELSR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...